0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TL1A

TL1A

Brief Information

Name:Tumor necrosis factor superfamily member 15
Target Synonym:TNLG1B,Vascular Endothelial Cell Growth Inhibitor,VEGI192A,Tumor Necrosis Factor Ligand Superfamily Member 15,Vascular Endothelial Growth Inhibitor-192A,VEGI,TNF Ligand-Related Molecule 1,TL1,Tumor Necrosis Factor Superfamily Member 15,Tumor Necrosis Fact
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TLA-H5243 Human Human TL1A / TNFSF15 Protein, His Tag (MALS verified)
TLA-H5243-structure
TLA-H5243-sds
TLA-H5243-elisa_1

Part of Bioactivity data

TLA-H5243-MALS-HPLC
Human TL1A, His Tag (Cat. No. ) MALS images

The purity of Human TL1A, His Tag(Cat. No. TLA-H5243) was more than 85% and the molecular weight of this protein is around 78-90 kDa verified by SEC-MALS.

Bioactivity-ELISA
Human TL1A, His TagHuman TL1A, His Tag (Cat. No. TLA-H5243) ELISA bioactivity

Immobilized Human DcR3, Fc Tag (Cat. No. TNB-H5255) at 5 μg/mL (100 μL/well) can bind Human TL1A, His Tag (Cat. No. TLA-H5243) with a linear range of 0.3-2 ng/mL (QC tested).

TLA-H5243-ELISA
Human TL1A, His TagHuman TL1A, His Tag (Cat. No. TLA-H5243) ELISA bioactivity

Immobilized Human DcR3, Fc Tag (Cat. No. TNB-H5255) at 5 μg/mL (100 μL/well) can bind Human TL1A, His Tag (Cat. No. TLA-H5243) with a linear range of 0.3-2 ng/mL (QC tested).

Synonym Name

TL1A, VEGI-251, TNFSF15

Background

TNF-like cytokine 1A (TL1A) and its receptors, death receptor 3 (DR3) and decoy receptor 3 (DcR3) are members of the TNF and TNF receptor superfamilies of proteins, respectively. Binding of APC-derived TL1A to lymphocytic DR3 provides co-stimulatory signals for activated lymphocytes. DR3 signaling affects not only the proliferative activity of and cytokine production by effector lymphocytes, but also critically influences the development and suppressive function of regulatory T-cells. Whereas, DcR3 restricts the function of the TL1A/DR3 complex: attenuating T-cell activation and downregulating the secretion of pro-inflammatory cytokines. Together with DR3 and DcR3, TL1A constitutes a cytokine system that actively interferes with the regulation of immune responses.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PF-06480605 PF-06480605 Phase 2 Clinical Pfizer Pharmaceuticals Ltd (China) Colitis, Ulcerative; Crohn Disease Details
PRA-023 PRA-023 Phase 2 Clinical Prometheus Biosciences Inc Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease Details

This web search service is supported by Google Inc.

totop